CoChat

A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

Open access
Weinblatt, Michael E., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovsky, Jiri, Guo, Xiang, White, Wendy I., Ryan, Patricia C., Godwood, Alex, Albulescu, Marius, Close, David, Burmester, Gerd R. · 2018 · Arthritis & Rheumatology
Cited by 100

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective: This 24‐week, phase II b, double‐blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte–macrophage colony‐stimulating factor receptor α) and golimumab (a monoclonal antibody to tumor necrosis factor [anti‐ TNF ]) in patients with rheumatoid arthritis ( RA ) who have had an inadequate response to disease‐modifying antirheumatic drugs ( DMARD s) (referred to as DMARD ‐ IR ) and/or inadequate response to other anti‐ TNF agents (referred to as anti‐ TNF – IR ). Methods: Patients with active RA and a history of DMARD ‐ IR (≥1 failed regimen) or DMARD ‐ IR (≥1 failed regimen) and anti‐ TNF – IR (1–2 failed regimens) were randomized 1:1 to receive either mavrilimumab 100 mg subcutaneously every other week or golimumab 50 mg subcutaneously every 4 weeks alternating with placebo every 4 weeks, administered concomitantly with methotrexate. The primary end points were the American College of Rheumatology 20% improvement ( ACR 20), 50% improvement, and 70% improvement response rates at week 24, percentage of patients achieving a Disease Activity Score in 28 joints using C‐reactive protein level ( DAS 28‐ CRP ) of <2.6 at week 24, percentage of patients with a score improvement of >0.22 on the Health Assessment Questionnaire ( HAQ ) disability index ( DI ) at week 24, and safety/tolerability measures. This study was not powered to formally compare the 2 treatments. Results: At week 24, differences in the ACR 20, ACR 50, and ACR 70 response rates between the mavrilimumab treatment group (n = 70) and golimumab treatment group (n = 68) were as follows: in all patients, −3.5% (90% confidence interval [90% CI ] −16.8, 9.8), −8.6% (90% CI −22.0, 4.8), and −9.8% (90% CI −21.1, 1.4), respectively; in the anti‐ TNF – IR group, 11.1% (90% CI −7.8, 29.9), −8.7% (90% CI −28.1, 10.7), and −0.7% (90% CI −18.0, 16.7), respectively. Differences in the percentage of patients achieving a DAS 28‐ CRP of <2.6 at week 24 between the mavrilimumab and golimumab groups were −11.6% (90% CI −23.2, 0.0) in all patients, and −4.0% (90% CI −20.9, 12.9) in the anti‐ TNF – IR group. The percentage of patients achieving a >0.22 improvement in the HAQ DI score at week 24 was similar between the treatment groups. Treatment‐emergent adverse events were reported in 51.4% of mavrilimumab‐treated patients and 42.6% of golimumab‐treated patients. No deaths were reported, and no specific safety signals were identified. Conclusion: The findings of this study demonstrate the clinical efficacy of both treatments, mavrilimumab at a dosage of 100 mg every other week and golimumab at a dosage of 50 mg every 4 weeks, in patients with RA . Both regimens were well‐tolerated in patients who had shown an inadequate response to DMARD s and/or other anti‐ TNF agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.40323

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 100

Metadata

Authors
Weinblatt, M. E., McInnes, I. B., Kremer, J. M., Miranda, P., Vencovsky, J., Guo, X., White, W. I., Ryan, P. C., Godwood, A., Albulescu, M., Close, D., & Burmester, G. R.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2017-12-27
Volume
70
Issue
1
Pages
49-59
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2759367587
Cited by
100
References
1
FWCI
7.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.